Dosing has now been completed in Annovis Bio's Phase 2a Trial of Posiphen (ANVS401).

PNT article:
Dosing Finished in Phase 2a Trial of ANVS401 for Parkinson's, Alzheimer's

This Phase 2a trial is described in the study record as a trial in two parts. The first part has 14 early PD patients and 14 early AD patients, taking either 80 mg daily of ANVS401 or placebo. Patient involvement in part 1 has been completed, and some interim results have been announced. The second part has 40 early PD patients taking 5 mg, 10 mg, 20 mg or 40 mg (no placebo). Patient involvement in part 2 has now also been completed.

Some commentators regard the (early) release of interim data from part 1 as "drip feeding" results from an ongoing trial. For example, see this SoPD blog post comment from Simon:

Monthly Research Review – June 2021 – The Science of Parkinson's

Personally, I'm giving them the benefit of the doubt.